| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
PRECISE-AD Phase 1b clinical trial in Alzheimer’s patients remains on track for unblinded 12-month topline data in the first quarter of 2027, including full safety, biomarker and cognitive outcomes data |
| 12 Nov 2026 |
8-K: Regulation FD Disclosure
Copyright 2026, ProMIS Neurosciences Inc., Non-confidential L E G A L D I S C L O S U R E S Forward-Looking Statements & Disclaimers This slide deck may contain certain forward-looking information and “forward-looking statements” that ar... |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company's Phase 1b trial of PMN310 in patients with early Alzheimer's disease (AD), including zero cases of amyloid-related imaging abnormalit... |
| 28 Jul 2026 |
8-K: Regulation FD Disclosure; Other Events
PRECISE-AD PMN310 · PHASE 1b BLINDED 6-MONTH INTERIM ANALYSIS Safety & Biomarker Assessment Update Blinded Interim Analysis Topline results expected Q1 2027 1 |
| 20 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
WHEREAS, Promis Neurosciences, Inc. (the “Company”) maintains the Promis Neurosciences, Inc. 2025 Stock Option and Incentive Plan (the “Plan”), which was previously adopted by the Board of Directors of the Company (the “Board”) and appro... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global investors. Proceeds are expected to fund the Company through 2027, including completion of the on... |
| 25 Mar 2026 |
8-K: Results of Operations and Financial Condition
PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027 |
| 30 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of January 29, 2026, by and among ProMIS Neurosciences Inc., a corporation incorporated under the Business Corporations Act (Ontario) (the “Company”), and the entities lis... |
| 16 Dec 2025 |
8-K: Other Events
On December 12, 2025, ProMIS Neurosciences Inc. (the “Company”) received a written notification from the Nasdaq Stock Market Listing Qualifications Staff indicating that the Company has regained compliance with the $1.00 minimum bid pric... |
| 24 Nov 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Other Events
Cambridge, Mass., November 24, 2025 – ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announce... |
| 19 Nov 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On November 17, 2025, ProMIS Neurosciences Inc. (the “Company”) held a special meeting of shareholders (the “Special Meeting”). The shareholders considered two proposals, each of which is described in more detail in the Company’s definit... |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
Cambridge, Massachusetts – November 12, 2025 ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurode... |
| 24 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group |
| 30 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On behalf of ProMIS Neurosciences Inc. (the “Company”), I am pleased to confirm the new terms of your employment with the Company. This Employment Offer letter (the “Employment Agreement”) shall supersede the offer letter dated January 2... |
| 03 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310 |
| 19 Aug 2025 |
8-K: Entry into a Material Definitive Agreement
ProMIS Neurosciences Inc., a corporation continued under the Business Corporations Act (Ontario) (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: |
| 13 Aug 2025 |
8-K: Results of Operations and Financial Condition
U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer’s Disease, enhancing program’s potential for priority review |
| 28 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of July 28, 2025, by and among ProMIS Neurosciences Inc., a corporation incorporated under the Business Corporations Act (Ontario) (the “Company”), and the entities listed... |
| 22 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of July 22, 2025, by and among ProMIS Neurosciences Inc., a corporation incorporated under the Business Corporations Act (Ontario) (the “Company”), and the entities listed... |
| 22 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
As previously disclosed, on January 5, 2024, ProMIS Neurosciences, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Agreement”) with BTIG, LLC, serving as agent (the “Agent”) with respect to an at-the-market of... |
Loading...